How to Revise Informed Consent Following Protocol Amendments in Clinical Trials

In the lifecycle of a clinical trial, changes to the protocol are common—whether due to safety findings, scientific advancements, regulatory updates, or operational needs. When such amendments affect the rights, safety, or well-being of participants, the informed consent form (ICF) must be revised and participants must be re-consented. This guide walks you through the why, when, and how of revising informed consent in line with regulatory requirements and best practices.

Why Re-Consent is Necessary After Protocol Changes:

Protocol amendments can impact participants in several ways. These may include changes in:

• Dosage, administration frequency, or treatment duration
• Inclusion/exclusion criteria
• Risk profile or new adverse events
• Trial procedures or frequency of visits
• Withdrawal rights or compensation clauses

Ethically, participants must be informed of these changes and have the opportunity to continue or withdraw based on the updated protocol. This aligns with ICH-GCP E6(R2), USFDA, and CDSCO guidelines.

When Should Informed Consent Be Revised?

Informed consent should be updated and re-administered when amendments:

• Introduce new risks or benefits
• Change study procedures involving participant commitment
• Modify key ethical considerations (e.g., inclusion criteria)
• Are flagged by regulatory authorities or ethics committees

Minor administrative changes (e.g., typos or contact details) may not require re-consent but should still be version-controlled.

Steps to Revise and Re-Implement Informed Consent:

1. Identify Changes That Require Re-Consent:

Collaborate with medical monitors, regulatory affairs, and safety teams to determine if an amendment warrants participant re-consent.

2. Draft Revised ICF:

• Use a clear, non-technical language to explain the changes
• Highlight modifications in risks, procedures, or rights
• Update version number and date prominently

Refer to your pharma SOP documentation on ICF development and version control.

3. Ethics Committee Approval:

Submit the revised ICF and protocol amendment to the Institutional Review Board (IRB) or Ethics Committee (EC). Provide:

• Tracked and clean versions of the revised ICF
• Rationale for the changes
• Communication plan for ongoing participants

No re-consenting can occur before EC approval.

4. Train Site Staff on New Procedures:

Ensure that investigators and site coordinators understand:

• The nature of the changes
• How to explain revisions to participants
• Documentation requirements and version use

Update site training logs and delegation logs accordingly to remain compliant with GMP compliance expectations.

5. Re-Consent Process with Participants:

Conduct one-on-one sessions with each enrolled subject. Ensure that:

• Revised consent is provided in the participant’s preferred language
• Time is given to review and ask questions
• A new signature is obtained on the revised ICF
• The reason for re-consent is documented in source notes

Witnesses are required for illiterate subjects or when required by protocol or EC.

Documentation and Version Control:

Accurate documentation of consent revisions is crucial for inspection readiness:

• Label revised ICFs clearly with version and date
• Maintain both signed old and new ICFs in the ISF
• Use validation master plan principles to track consent workflow
• Update the Informed Consent Log and screening checklist

Handling Participants Who Refuse Re-Consent:

If a participant chooses not to continue under the revised protocol:

• Document the reason and date of withdrawal
• Report to the sponsor and Ethics Committee
• Ensure any follow-up per protocol for early withdrawals is completed

This decision must be respected and must not affect the subject’s access to standard medical care.

Managing eConsent During Protocol Amendments:

If using an eConsent system:

• Update digital templates with new version and content
• Re-validate system outputs per clinical trial documentation standards
• Re-capture digital signatures and audit trails

Common Audit Observations Related to Re-Consent:

• Using outdated ICF versions for new enrollments
• Failure to re-consent enrolled participants after significant amendments
• Missing EC approval for revised ICF
• Poorly documented re-consent process in source notes

These issues can lead to findings in inspections by EMA, FDA, or national agencies.

Checklist for Re-Consenting Participants:

1. Confirm need for re-consent based on amendment
2. Prepare revised ICF (translated if needed)
3. Submit to and obtain EC approval
4. Train site staff on the update
5. Conduct re-consent sessions
6. Update logs and ISF with new documentation
7. Ensure no old version is used after cutoff date

Conclusion:

Re-consenting participants after protocol amendments is not just a regulatory requirement—it is a matter of ethical transparency and participant protection. A well-managed re-consent process upholds the integrity of the study and fosters trust between participants and researchers. By following structured SOPs, ensuring proper documentation, and engaging with ethics committees, clinical trial teams can seamlessly manage consent revisions across the study lifecycle.